Notice: This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrends XTLB vs. ATHE, CVKD, GDTC, IRD, MRNS, CALC, XCUR, VRCA, RLYB, and PULMShould you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Alterity Therapeutics (ATHE), Cadrenal Therapeutics (CVKD), CytoMed Therapeutics (GDTC), Opus Genetics (IRD), Marinus Pharmaceuticals (MRNS), CalciMedica (CALC), Exicure (XCUR), Verrica Pharmaceuticals (VRCA), Rallybio (RLYB), and Pulmatrix (PULM). These companies are all part of the "pharmaceutical preparations" industry. XTL Biopharmaceuticals vs. Alterity Therapeutics Cadrenal Therapeutics CytoMed Therapeutics Opus Genetics Marinus Pharmaceuticals CalciMedica Exicure Verrica Pharmaceuticals Rallybio Pulmatrix Alterity Therapeutics (NASDAQ:ATHE) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability. Does the MarketBeat Community prefer ATHE or XTLB? XTL Biopharmaceuticals received 74 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 71.82% of users gave XTL Biopharmaceuticals an outperform vote while only 62.50% of users gave Alterity Therapeutics an outperform vote. CompanyUnderperformOutperformAlterity TherapeuticsOutperform Votes562.50% Underperform Votes337.50% XTL BiopharmaceuticalsOutperform Votes7971.82% Underperform Votes3128.18% Do institutionals & insiders have more ownership in ATHE or XTLB? 2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is ATHE or XTLB more profitable? Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A XTL Biopharmaceuticals N/A N/A N/A Do analysts rate ATHE or XTLB? Alterity Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 230.58%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than XTL Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50XTL Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, ATHE or XTLB? Alterity Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Does the media prefer ATHE or XTLB? In the previous week, Alterity Therapeutics' average media sentiment score of 0.00 equaled XTL Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Alterity Therapeutics Neutral XTL Biopharmaceuticals Neutral Which has higher valuation and earnings, ATHE or XTLB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$12.54MN/AN/AXTL BiopharmaceuticalsN/AN/A-$1.78MN/AN/A SummaryXTL Biopharmaceuticals beats Alterity Therapeutics on 5 of the 9 factors compared between the two stocks. Remove Ads Get XTL Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XTLB vs. The Competition Export to ExcelMetricXTL BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.23M$7.11B$5.72B$8.00BDividend YieldN/A2.72%4.89%4.03%P/E RatioN/A6.3024.9018.90Price / SalesN/A219.97401.45115.03Price / CashN/A65.6738.0534.62Price / Book3.136.387.274.15Net Income-$1.78M$140.25M$3.19B$246.75M XTL Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XTLBXTL BiopharmaceuticalsN/A$1.29-30.9%N/A+39.7%$8.23MN/A0.00N/AGap DownATHEAlterity Therapeutics2.4952 of 5 stars$3.64-3.7%$8.00+119.8%+112.9%$31.82MN/A0.0010Positive NewsCVKDCadrenal Therapeutics2.6136 of 5 stars$17.40-8.4%$32.00+83.9%N/A$31.02MN/A-2.614GDTCCytoMed Therapeutics2.138 of 5 stars$2.81+0.4%$5.00+77.9%+21.4%$30.74MN/A0.00N/APositive NewsGap DownIRDOpus Genetics2.6968 of 5 stars$0.97-5.7%$8.00+723.2%N/A$30.68M$8.38M-0.8914Upcoming EarningsGap UpMRNSMarinus Pharmaceuticals4.1537 of 5 stars$0.55-0.2%$4.79+771.6%-93.8%$30.32M$30.99M-0.22110Analyst ForecastNews CoverageCALCCalciMedica2.2699 of 5 stars$2.20-0.9%$18.00+718.2%-51.8%$29.66MN/A-2.0430XCURExicure1.779 of 5 stars$11.32+19.8%N/A+1,521.2%$29.50M$500,000.00-5.4750Gap UpVRCAVerrica Pharmaceuticals3.966 of 5 stars$0.64-1.4%$9.50+1,384.1%-87.3%$29.19M$9.21M-0.3540Upcoming EarningsRLYBRallybio2.4831 of 5 stars$0.69-4.3%$9.75+1,311.0%-64.3%$28.67M$598,000.00-0.4340Upcoming EarningsPULMPulmatrix0.3268 of 5 stars$7.79-3.6%N/A+255.0%$28.45M$10.01M-2.9520Positive News Remove Ads Related Companies and Tools Related Companies Alterity Therapeutics Competitors Cadrenal Therapeutics Competitors CytoMed Therapeutics Competitors Opus Genetics Competitors Marinus Pharmaceuticals Competitors CalciMedica Competitors Exicure Competitors Verrica Pharmaceuticals Competitors Rallybio Competitors Pulmatrix Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XTLB) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
